Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Pharmacol Res. 2012 Nov 2;67(1):94–109. doi: 10.1016/j.phrs.2012.10.013

Fig. 4.

Fig. 4

FAAH (URB597, URB937) and MGL (JZL184) inhibitors suppress cisplatin-induced mechanical allodynia through CB1 and CB2 but not TRPA1 receptor mechanisms whereas FAAH inhibitors additionally engage TRPV1 dependent mechanisms. (a) The CB1 (AM251; 3 mg/kg i.p.), CB2 (AM630; 3 mg/kg i.p.), TRPV1 (AMG9810; 3 mg/kg) and TRPA1 (HC030031; 8 mg/kg) antagonists did not alter cisplatin-induced mechanical allodynia relative to vehicle treatment (i.p.). (b) JZL184 (8 mg/kg i.p.), (c) URB597 (1 mg/kg i.p.) and (d) URB937 (1 mg/kg i.p.) suppressed cisplatin-induced mechanical allodynia through mechanisms blocked by either the CB1 (AM251; 3 mg/kg i.p.) or the CB2 (AM630; 3 mg/kg i.p.) antagonists, but not the TRPA1 (HC030031; 8 mg/kg i.p) antagonist. Anti-allodynic effects of FAAH (URB597, URB937), but not MGL (JZL184), inhibitors were also blocked by the TRPV1 (AMG9810; 3 mg/kg i.p.) antagonist. Data are expressed as mean ± s.e.m. (n = 6 per group). * P < 0.001 vs. DMSO, AM251 + MGL/FAAH inhibitors, AM630 + MGL/FAAH inhibitors and AMG9810 + FAAH inhibitors (ANOVA, Bonferroni post hoc).